Jiangsu Recbio Technology Co., Ltd.

Biological E, an Indian pharmaceutical manufacturer, has partnered with China’s Recbio to produce and commercialize the REC603 HPV9 vaccine, marking a significant step in combating HPV-related cancers. Designed to protect against nine strains of Human Papillomavirus (HPV), the vaccine targets cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts. Globally, HPV infections are linked to 620,000 cancer cases in women and 70,000 in men annually. Under the agreement, Recbio will supply drug substances and transfer technology for formulation, filling, and packaging to Biological E. This collaboration also grants Biological E access to global tender markets, including UNICEF and the Pan American Health Organization (PAHO). Recbio’s REC603 is currently undergoing Phase III clinical trials in China and is designed for individuals aged 9 to 45. Large-scale manufacturing by Biological E in India will begin after the technology transfer, ensuring affordable doses for both domestic and international markets. Dr. Liu Yong, CEO of Recbio, stated, “This partnership accelerates the global availability of the HPV9 vaccine, addressing the growing demand for more affordable cervical cancer prevention solutions.” This agreement positions Recbio for international expansion while leveraging Biological E’s manufacturing expertise to improve vaccine accessibility worldwide.

Hyderabad: Chinese biopharmaceutical company ,Jiangsu Recbio Technology Company Limited (02179.HK) has entered into a licensing and technology transfer agreement with Biological E . Limited (BE), an Indian vaccine and pharmaceutical manufacturer, for the production and commercialisation of its recombinant 9-valent HPV (HPV9) vaccine, REC603. Under the agreement, Recbio will supply the drug substance (DS) and transfer the formulation, filling, and packaging technology to BE.The agreement also grants BE rights to participate in global tenders issued by UNICEF and the Pan American Health Organization (PAHO). The HPV9 vaccine is designed to protect against nine strains of human papillomavirus associated with cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts.In 2019, HPV infections were linked to an estimated 620,000 cancer cases in women and 70,000 in men globally. Designed for individuals aged 9 to 45, Recbio’s REC603 is currently in Phase III clinical trials in China. Once the technology transfer is complete, BE will begin large-scale production in India, aiming to improve domestic access and supply affordable doses to global markets. Recbio has initiated the transfer of technical know-how, materials, and documentation to enable local production by BE. The company will continue to support BE through clinical development and regulatory processes to ensure timely market entry. The collaboration comes amid growing global demand for affordable cervical cancer prevention . Leveraging BE’s manufacturing capacity, the partnership aims to improve HPV vaccine availability in India and other regions Dr. Liu Yong, Founder, Chairman, and CEO of Recbio, expressed confidence in the partnership, stating, “This cooperation marks significant progress for Recbio’s international expansion. Together with BE, we aim to accelerate the launch of the HPV9 vaccine in India and globally.” Large-scale manufacturing is expected to commence following the completion of the technology transfer. The agreement represents Recbio’s entry into the Indian and global vaccine markets and underscores its expansion in the field of innovative immunizations. By Online Bureau ,

Ab&B Bio-Tech\'s pipeline puts it on a collision course with U.S. drugmakers. \n Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with companies including GSK, Merck & Co. and Pfizer.China-based Ab&B won approval for a quadrivalent flu vaccine in its home market in 2023. The flu shot is one of two core products that will swallow up around half of the anticipated IPO haul. Ab&B’s other core product is a rabies vaccine candidate that is scheduled to enter phase 3 in the second or third quarter. China already has 23 approved human rabies vaccines but only two that use similar tech to Ab&B’s shot.Ab&B will go up against other local manufacturers if it launches the rabies vaccine in China but the rest of its pipeline could pit it against big Western drugmakers. The biotech has allocated around one-quarter of the expected IPO monies to advancing the rest of its portfolio.A phase 3 trial of a 23-valent pneumococcal disease vaccine candidate is the biggest anticipated outlay in the non-core pipeline. Ab&B plans to start the study around the end of the year. If successful, the trial will position Ab&B to enter a market that is already served by Merck’s 23-valent vaccine Pneumovax and Pfizer’s 13-valent shot Prevnar 13. Another Ab&B program puts the biotech on a collision course with GSK. A phase 1 trial of a shingles shot is set to start this quarter. Currently, GSK’s Shingrix is the only recombinant vaccine against herpes zoster, also known as shingles, approved for use in China. However, Ab&B’s chances of launching the second recombinant shot look slim, with Recbio, Lvzhu Biotech and MaxVax already in phase 3.Ab&B has also ceded a head start to its rivals in the respiratory syncytial virus (RSV) vaccine race. China is yet to approve a RSV vaccine, unlike the U.S. which has given the green light to shots from GSK, Moderna and Pfizer, but multiple candidates have reached the clinic ahead of Ab&B. A filing to test Ab&B’s vaccine candidate in humans is planned for around the middle of the year.The biotech is seeking funding for the programs from investors who have plenty of IPOs to pick from. Ab&B is one of eight biotechs that have filed to go public in Hong Kong over the past month and one of three to file paperwork this week. The filings have swelled the backlog of biotech IPOs toward 20, with Duality Biotherapeutics, Zephyrm Bioscience and other companies that filed last year still in the queue.